SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma
W Zhang, J Fan, Q Chen, C Lei, B Qiao… - Oncology …, 2018 - spandidos-publications.com
Overdue treatment and prognostic evaluation lead to low survival rates in patients with lung
adenocarcinoma (LUAD). To date, effective biomarkers for prognosis are still required. The …
adenocarcinoma (LUAD). To date, effective biomarkers for prognosis are still required. The …
Preoperative pulmonary rehabilitation for marginal-function lung cancer patients
A Hashmi, FA Baciewicz Jr… - Asian …, 2017 - journals.sagepub.com
Background This study aimed to evaluate the impact of preoperative pulmonary
rehabilitation in lung cancer patients undergoing pulmonary resection surgery with marginal …
rehabilitation in lung cancer patients undergoing pulmonary resection surgery with marginal …
Nimotuzumab combined with gemcitabine and cisplatin as second‐line chemotherapy for advanced non‐small‐cell lung cancer
H Wang, Y Ren, Z Qian, K Fu, H Zhang, W Li… - Thoracic …, 2012 - Wiley Online Library
Objective: To evaluate the efficacy and safety of nimotuzumab combined with gemcitabine
and cisplatin as second‐line chemotherapy for advanced non‐small‐cell lung cancer …
and cisplatin as second‐line chemotherapy for advanced non‐small‐cell lung cancer …